CY1502A - Pharmaceutical compositions containing n-substituted-3-hydroxypyrid-2-one or-4-one derivatives - Google Patents

Pharmaceutical compositions containing n-substituted-3-hydroxypyrid-2-one or-4-one derivatives

Info

Publication number
CY1502A
CY1502A CY1502A CY150283A CY1502A CY 1502 A CY1502 A CY 1502A CY 1502 A CY1502 A CY 1502A CY 150283 A CY150283 A CY 150283A CY 1502 A CY1502 A CY 1502A
Authority
CY
Cyprus
Prior art keywords
hydroxypyrid
derivatives
substituted
pharmaceutical compositions
compositions containing
Prior art date
Application number
CY1502A
Other languages
English (en)
Inventor
Robert Charles Hider
George Kontoghiorghes
Jack Silver
Original Assignee
Nat Res Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Res Dev filed Critical Nat Res Dev
Publication of CY1502A publication Critical patent/CY1502A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
CY1502A 1982-03-24 1983-03-24 Pharmaceutical compositions containing n-substituted-3-hydroxypyrid-2-one or-4-one derivatives CY1502A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8208608 1982-03-24

Publications (1)

Publication Number Publication Date
CY1502A true CY1502A (en) 1990-08-03

Family

ID=10529232

Family Applications (1)

Application Number Title Priority Date Filing Date
CY1502A CY1502A (en) 1982-03-24 1983-03-24 Pharmaceutical compositions containing n-substituted-3-hydroxypyrid-2-one or-4-one derivatives

Country Status (8)

Country Link
US (1) US4840958A (de)
EP (1) EP0093498B1 (de)
JP (3) JPS58174319A (de)
CY (1) CY1502A (de)
DE (2) DE19975062I1 (de)
GR (1) GR78491B (de)
HK (1) HK6190A (de)
NL (1) NL990031I2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308055D0 (en) * 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
EP0305646B1 (de) * 1983-03-24 1996-11-13 Btg International Limited 3-Hydroxypyrid-4-one und pharmazeutische Zusammensetzungen
GB8308054D0 (en) * 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
GB8325494D0 (en) * 1983-09-23 1983-10-26 Hider R C Pharmaceutical compositions
US4912118A (en) * 1983-09-23 1990-03-27 National Research Development Corporation Pharmaceutical compositions
USRE34313E (en) * 1983-09-23 1993-07-13 National Research Development Corporation Pharmaceutical compositions
EP0335745A1 (de) * 1988-03-31 1989-10-04 The Royal Free Hospital School Of Medicine Verfahren zur Herstellung von Pyridin-4-onen
GB8910521D0 (en) * 1989-05-08 1989-06-21 Nat Res Dev The stabilization of organic compounds
US5298525A (en) * 1992-11-23 1994-03-29 University Technologies International, Inc. Diabetes prevention and treatment
US6046219A (en) * 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5849587A (en) * 1995-06-09 1998-12-15 Cornell Research Foundation, Inc. Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells
ES2230564T3 (es) 1995-06-10 2005-05-01 Vitra Pharmaceuticals Ltd. Compuestos ferricos, composiciones, metodos de fabricacion de estos y sus utilizacioneds.
US6004986A (en) * 1997-05-08 1999-12-21 The University Of Virginia Patent Foundation Method for treating cerebral vasospasm and cerebral ischemia using iron chelators and pharmaceutical compositions therefor
US6767741B1 (en) * 1999-08-27 2004-07-27 Invitrogen Corporation Metal binding compounds and their use in cell culture medium compositions
IL135884A (en) * 2000-04-30 2005-08-31 Yissum Res Dev Co Method for measuring non-transferrin bound iron
AU2001287850A1 (en) * 2000-09-19 2002-04-02 Vitra Pharmaceuticals Limited Iron compositions
US6426418B1 (en) 2001-11-02 2002-07-30 Apotex, Inc. Processes for the manufacturing of 3-hydroxy-N,1,6-trialkyl-4-oxo-1,4-dihydropyridine-2-carboxamide
GB0211500D0 (en) 2002-05-18 2002-06-26 Vitra Pharmaceuticals Ltd Method of forming iron hydroxypyrone compounds
EP2295980A1 (de) 2002-10-30 2011-03-16 Yissum Research Development Company, of The Hebrew University of Jerusalem Moleküle und diese verwendende Verfahren zur Messung von nicht-transferringebundenem Eisen
US8058442B2 (en) 2002-11-07 2011-11-15 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
CA2488034C (en) * 2004-11-19 2009-10-06 Apotex Inc. Process for the manufacture of 3-hydroxy-n-alkyl-1-cycloalkyl-6-alkyl-4-oxo-1,4-dihydropyridine-2-carboxamide and its related analogues
CA2789474A1 (en) * 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
GB201007209D0 (en) 2010-04-29 2010-06-16 King S College London Compound
WO2012137202A1 (en) 2011-04-05 2012-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci)
US10821103B2 (en) 2016-11-07 2020-11-03 Arbutus Biopharma Corporation Substituted pyridinone-containing trycyclic compounds, and methods using same
WO2019177937A1 (en) 2018-03-12 2019-09-19 Arbutus Biopharma, Inc. Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same
CA3096687A1 (en) 2018-04-12 2019-10-17 Arbutus Biopharma Corporation Methods for preparing substituted pyridinone-containing tricyclic compounds

Also Published As

Publication number Publication date
US4840958A (en) 1989-06-20
EP0093498B1 (de) 1986-11-26
JPH0460987B2 (de) 1992-09-29
JPH0515693B2 (de) 1993-03-02
EP0093498A2 (de) 1983-11-09
HK6190A (en) 1990-02-02
JPS58174319A (ja) 1983-10-13
EP0093498A3 (en) 1984-07-11
NL990031I2 (nl) 2000-04-03
GR78491B (de) 1984-09-27
DE3367849D1 (en) 1987-01-15
JPS58174318A (ja) 1983-10-13
NL990031I1 (nl) 1999-12-01
DE19975062I1 (de) 2003-09-04
JPH0680636A (ja) 1994-03-22
JPH0757749B2 (ja) 1995-06-21

Similar Documents

Publication Publication Date Title
DE3367849D1 (en) Pharmaceutical compositions containing n-substituted-3-hydroxypyrid-2-one or -4-one derivatives
GB8326565D0 (en) Pharmaceutical compositions
GB8327612D0 (en) Pharmaceutical compositions
SG93290G (en) Pharmaceutical compositions containing 1-hydroxypyrid-2-one derivatives
ZA833781B (en) Pharmaceutical compositions
EP0093551A3 (en) Pharmaceutical composition
GB2118176B (en) Pharmaceutical compositions
GB2117766B (en) Pharmaceutical compositions
PT77323B (en) Pharmaceutical compositions
GB8429749D0 (en) Pharmaceutical compositions
GB8313814D0 (en) Pharmaceutical compositions
IL69294A0 (en) Pharmaceutical compositions containing sugar derivatives
GB8329700D0 (en) Anti-haemophilic pharmaceutical composition
DE3377696D1 (en) Pharmaceutical compositions
US4594359B1 (en) Pharmaceutical compositions
GB8328896D0 (en) Pharmaceutical composition
GB2114001B (en) Nasel pharmaceutical compositions
IL67881A0 (en) Pharmaceutical compositions including certain cholecalciferol derivatives
GB8305028D0 (en) Pharmaceutical compositions
GB8314736D0 (en) Pharmaceutical compositions
GB8330810D0 (en) Pharmaceutical compositions
GB8331068D0 (en) Pharmaceutical compositions
GB8329391D0 (en) Pharmaceutical compositions
GB8314540D0 (en) Pharmaceutical composition
DE3372706D1 (en) Pharmaceutical compositions